Your browser doesn't support javascript.
loading
Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma.
Nijland, Marcel; van Meerten, Tom; Seitz, Annika; Huls, Gerwin; Kibbelaar, Robby; Visser, Lydia; van den Berg, Anke; Diepstra, Arjan.
Afiliação
  • Nijland M; Department of Hematology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. m.nijland@umcg.nl.
  • van Meerten T; Department of Hematology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Seitz A; Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
  • Huls G; Department of Hematology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Kibbelaar R; Department of Pathology, Pathology Friesland, Leeuwarden, the Netherlands.
  • Visser L; Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
  • van den Berg A; Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
  • Diepstra A; Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Ann Hematol ; 97(5): 905-907, 2018 May.
Article em En | MEDLINE | ID: mdl-29327077

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Linfoma de Células B / Terapia de Salvação / Inibidores de Proteínas Quinases / Janus Quinase 1 / Janus Quinase 2 / Terapia de Alvo Molecular / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Linfoma de Células B / Terapia de Salvação / Inibidores de Proteínas Quinases / Janus Quinase 1 / Janus Quinase 2 / Terapia de Alvo Molecular / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article